|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Belani CP: Chemotherapy regimens in
advanced non-small-cell lung cancer: Recent randomized trials. Clin
Lung Cancer. 3(Suppl 1): S5–S9. 2002. View Article : Google Scholar
|
|
3
|
Suehisa H and Toyooka S: Adjuvant
chemotherapy for completely resected non-small-cell lung cancer.
Acta Med Okayama. 63:223–230. 2009.PubMed/NCBI
|
|
4
|
Li CH, Cai L, Chen XS, Meng QW and Sui GJ:
DDP-sensitivity-related genes in 10 lung cancer cell lines.
Zhonghua Zhong Liu Za Zhi. 30:418–421. 2008.In Chinese. PubMed/NCBI
|
|
5
|
Shen Y, Ren M, Shi Y, Zhang Y and Cai Y:
Octreotide enhances the sensitivity of the SKOV3/DDP ovarian cancer
cell line to cisplatin chemotherapy in vitro. Exp Ther Med.
2:1171–1176. 2011.
|
|
6
|
Weng Y, Wang Y, Shi Y, Zhou W, Wang H and
Wang C: TLR9 expression and its role in chemosensitivity to DDP in
human cervical cancer cells in vitro. J Huazhong Univ Sci Technolog
Med Sci. 31:550–554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen J, Solomides C, Parekh H, Simpkins F
and Simpkins H: Cisplatin resistance in human cervical, ovarian and
lung cancer cells. Cancer Chemother Pharmacol. 75:1217–1227. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen Y, Gao Y, Zhang K, Li C, Pan Y, Chen
J, Wang R and Chen L: MicroRNAs as regulators of cisplatin
resistance in lung cancer. Cell Physiol Biochem. 37:1869–1880.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Müller CB, De Bastiani MA, Becker M,
França FS, Branco MA, Castro MA and Klamt F: Potential crosstalk
between cofilin-1 and EGFR pathways in cisplatin resistance of
non-small-cell lung cancer. Oncotarget. 6:3531–3539. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang H, Hui KM, Xu S, Chen Y, Wong JT and
Xue H: Two flavones from Scutellaria baicalensis Georgi and their
binding affinities to the benzodiazepine site of the GABAA receptor
complex. Pharmazie. 57:857–858. 2002.
|
|
11
|
Hui KM, Wang XH and Xue H: Interaction of
flavones from the roots of Scutellaria baicalensis with the
benzodiazepine site. Planta Med. 66:91–93. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu Z, Wang F, Tsang SY, Ho KH, Zheng H,
Yuen CT, Chow CY and Xue H: Anxiolytic-like effect of baicalin and
its additivity with other anxiolytics. Planta Med. 72:189–192.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liao JF, Hung WY and Chen CF:
Anxiolytic-like effects of baicalein and baicalin in the Vogel
conflict test in mice. Eur J Pharmacol. 464:141–146. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tarragó T, Kichik N, Claasen B, Prades R,
Teixidó M and Giralt E: Baicalin, a prodrug able to reach the CNS,
is a prolyl oligopeptidase inhibitor. Bioorg Med Chem.
16:7516–7524. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takahashi H, Chen MC, Pham H, Angst E,
King JC, Park J, Brovman EY, Ishiguro H, Harris DM, Reber HA, et
al: Baicalein, a component of Scutellaria baicalensis, induces
apoptosis by Mcl-1 downregulation in human pancreatic cancer cells.
Biochim Biophys Acta. 1813:1465–1474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Z, Lv J, Lei X, Li S, Zhang Y, Meng
L, Xue R and Li Z: Baicalein reduces the invasion of glioma cells
via reducing the activity of p38 signaling pathway. PLoS One.
9:e903182014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen K, Zhang S, Ji Y, Li J, An P, Ren H,
Liang R, Yang J and Li Z: Baicalein inhibits the invasion and
metastatic capabilities of hepatocellular carcinoma cells via
downregulation of the ERK pathway. PLoS One. 8:e729272013.
View Article : Google Scholar
|
|
18
|
Dickey CA, Koren J, Zhang YJ, Xu YF,
Jinwal UK, Birnbaum MJ, Monks B, Sun M, Cheng JQ, Patterson C, et
al: Akt and CHIP coregulate tau degradation through coordinated
interactions. Proc Natl Acad Sci USA. 105:3622–3627. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peltier J, O'Neill A and Schaffer DV:
PI3K/Akt and CREB regulate adult neural hippocampal progenitor
proliferation and differentiation. Dev Neurobiol. 67:1348–1361.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jin ZJ: About the evaluation of drug
combination. Acta Pharmacol Sin. 25:146–147. 2004.PubMed/NCBI
|
|
21
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Apps MG, Choi EH and Wheate NJ: The
state-of-play and future of platinum drugs. Endocr Relat Cancer.
22:R219–R233. 2015.PubMed/NCBI
|
|
23
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Murata T, Haisa M, Uetsuka H, Nobuhisa T,
Ookawa T, Tabuchi Y, Shirakawa Y, Yamatsuji T, Matsuoka J,
Nishiyama M, et al: Molecular mechanism of chemoresistance to
cisplatin in ovarian cancer cell lines. Int J Mol Med. 13:865–868.
2004.PubMed/NCBI
|
|
25
|
Wu HM, Jiang ZF, Ding PS, Shao LJ and Liu
RY: Hypoxia-induced autophagy mediates cisplatin resistance in lung
cancer cells. Sci Rep. 5:122912015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Im JY, Lee KW, Won KJ, Kim BK, Ban HS,
Yoon SH, Lee YJ, Kim YJ, Song KB and Won M: DNA damage-induced
apoptosis suppressor (DDIAS), a novel target of NFATc1, is
associated with cisplatin resistance in lung cancer. Biochim
Biophys Acta. 1863:40–49. 2016. View Article : Google Scholar
|
|
27
|
Yang Y, Zhang P, Zhao Y, Yang J, Jiang G
and Fan J: Decreased MicroRNA-26a expression causes cisplatin
resistance in human non-small cell lung cancer. Cancer Biol Ther.
17:515–525. 2016. View Article : Google Scholar :
|
|
28
|
Wu DW, Lee MC, Hsu NY, Wu TC, Wu JY, Wang
YC, Cheng YW, Chen CY and Lee H: FHIT loss confers cisplatin
resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA
reduction. Oncogene. 34:3882–3883. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu C, Wangpaichitr M, Feun L, Kuo MT,
Robles C, Lampidis T and Savaraj N: Overcoming cisplatin resistance
by mTOR inhibitor in lung cancer. Mol Cancer. 4:252005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li JH, Luo N, Zhong MZ, Xiao ZQ, Wang JX,
Yao XY, Peng Y and Cao J: Inhibition of microRNA-196a may reverse
cisplatin resistance of A549/DDP non-small-cell lung cancer cell
line. Tumour Biol. 37:2387–2394. 2016. View Article : Google Scholar
|
|
31
|
Wang CK, Zhang Y, Zhang ZJ, Qiu QW, Cao JG
and He ZM: Effects of VBMDMP on the reversal of cisplatin
resistance in human lung cancer A549/DDP cells. Oncol Rep.
33:372–382. 2015.
|
|
32
|
Li X, Yang G, Li X, Zhang Y, Yang J, Chang
J, Sun X, Zhou X, Guo Y, Xu Y, et al: Traditional Chinese medicine
in cancer care: A review of controlled clinical studies published
in Chinese. PLoS One. 8:e603382013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dong J, Su SY, Wang MY and Zhan Z: Shenqi
fuzheng, an injection concocted from Chinese medicinal herbs,
combined with platinum-based chemotherapy for advanced non-small
cell lung cancer: A systematic review. J Exp Clin Cancer Res.
29:1372010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lichti-Kaiser K and Staudinger JL: The
traditional Chinese herbal remedy tian xian activates pregnane X
receptor and induces CYP3A gene expression in hepatocytes. Drug
Metab Dispos. 36:1538–1545. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sui X, Chen R, Wang Z, Huang Z, Kong N,
Zhang M, Han W, Lou F, Yang J, Zhang Q, et al: Autophagy and
chemotherapy resistance: A promising therapeutic target for cancer
treatment. Cell Death Dis. 4:e8382013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hubaux R, Thu KL, Vucic EA, Pikor LA, Kung
SH, Martinez VD, Mosslemi M, Becker-Santos DD, Gazdar AF, Lam S, et
al: Microtubule affinity-regulating kinase 2 is associated with DNA
damage response and cisplatin resistance in non-small cell lung
cancer. Int J Cancer. 137:2072–2082. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu LZ, Zhou XD, Qian G, Shi X, Fang J and
Jiang BH: AKT1 amplification regulates cisplatin resistance in
human lung cancer cells through the mammalian target of
rapamycin/p70S6K1 pathway. Cancer Res. 67:6325–6332. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Duan S, Tsai Y, Keng P and Chen Y, Lee SO
and Chen Y: IL-6 signaling contributes to cisplatin resistance in
non-small cell lung cancer via the upregulation of anti-apoptotic
and DNA repair associated molecules. Oncotarget. 6:27651–27660.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang YS, Xue Z and Zhang H: Sorafenib
reverses resistance of gastric cancer to treatment by cisplatin
through downregulating MDR1 expression. Med Oncol. 32:4702015.
View Article : Google Scholar
|
